Kyowa Kirin (4151 JP): 1H26 Revenue Grow on North America, EMEA; Guidance Reiterated
Kyowa Kirin posted 14% revenue growth in 1H26, margin expanded and the company reiterated 2026 guidance. Company needs new drugs to augment growth....
106 Views
Top APAC (Ex-China) Investment Worthy Healthcare Companies Using Smartkarma’s Smart Score Screener
We have screened APAC (ex-China) healthcare companies with market cap≥$800M using Smartkarma’s Smart Score and picked up 2 investable ideas by...
635 Views
Primer: Kyowa Kirin Co Ltd (4151 JP) - Aug 2026
Kyowa Kirin is a global specialty pharmaceutical company with a strong focus on developing innovative drugs for oncology, nephrology, and rare...
103 Views
APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
96 Views
Kyowa Kirin (4151 JP): 1Q26 Revenue Grow on EMEA & Out-Licensing, Guidance Partially Revised
Kyowa Kirin sees strong revenue growth in 1Q26, with improved margins and revised profit guidance for 2026. Company looks to new drugs for future...
236 Views